The expansion addresses sustained demand particularly for cell and gene therapy services, says Scottish CDMO Symbiosis. Contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services has completed a £1.5 million ($1.8 million) expansion at its site in Stirling, UK – about 40 miles northwest of Scottish capital Edinburgh. The investment increases the firm’s output by about 25%, CEO Colin MacKay told this publication, and will help feed the demand aseptic GMP manufacturing (fill/finish) services. “Expansion of the business relates specifically…